The Anti-Migraine Market 2007-2022 - market research report

Chapter 1 Executive Summary
Chapter 2 Introduction: 2.1 What are Migraines

2.1.1 What Causes Migraine?

2.1.2 Symptom Phases of Migraine

2.1.2.1 Prodrome Phase

2.1.2.2 Auras Phase

2.1.2.3 Attack Phase

2.1.2.4 Postdrome Phase; 2.2 What is Headache Pain?

2.2.1 Tension Headaches

2.2.2 Cluster Headaches; 2.3 Which Drugs are Approved for Migraine Treatment?

2.3.1 Acute Symptomatic Relief of Migraine Pain

2.3.1.1 What are the Triptans?

2.3.1.1.1 Sumatriptan (Imitrex, Imigran, Imigran Recovery)

2.3.1.1.2 Rizatriptan (Maxalt)

2.3.1.1.3 Zolmitriptan (Zomig)

2.3.1.1.4 Eletriptan (Relpax)

2.3.1.1.5 Naratriptan (Naramig)

2.3.1.1.6 Almotriptan (Axert, Almogran)

2.3.1.1.7 Frovatriptan (Frova)

2.3.1.2 Which Ergots have the FDA Approved for Migraine Treatment?

2.3.1.2.1 Side Effects of Ergots

2.3.1.2.2 Withdrawal of Drug

2.3.1.3 Which Analgesics Have the FDA Approved for Migraine Treatment?

2.3.1.4 Which Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Have Been Approved by the FDA?; 2.4 Opioids on the Market; 2.5 Beta Blockers on the Market; 2.6 Anticonvulsants for Migraine (Depakote and Topamax); 2.7 Antidepressants; 2.8 Calcium-Channel Blockers; 2.9 Other Drug Classes Under Investigation
Chapter 3 The Global Anti-Migraine Market: 3.1 The Global Anti-Migraine Market Analysis

3.1.1 GSK's Blockbuster Migraine Drug Imitrex Faces Loss of Sales

3.1.1.1 GSK Waiting Approval for New Potential Anti-Migraine Blockbuster Drug

3.1.2 AstraZeneca's Zomig - The New Market Leader Perhaps?

3.1.3 Relpax Shows Positive Growth

3.1.4 What Does the Future Hold for Migraine Therapy?

3.1.5 What are the Unmet Needs in the Management of Migraine?

3.1.6 Visiongain Believes That Significant Advances Will Occur in this Market with Potentially High Revenues for Next-Generation Products

3.1.7 GSK Currently Leads the Anti-Migraine Market

3.1.8 Imitrex will be Overtaken by Zomig as the Leading Anti-Migraine Product

3.1.9 The Top Ten Countries in the Anti-Migraine Market
Chapter 4 Forces Affecting the Anti-Migraine Market: 4.1 SWOT Analysis of the Anti-Migraine Market

4.1.1 Market Drivers

4.1.2 Market Restraints

4.1.3 Why Growth in the Market is Expected?; 4.2 Success of the Triptan Drugs

4.2.1 Niche Markets and the Success of the Triptan

4.2.2 What are the Therapeutic Advantages Offered by the Newer Triptans?

4.2.3 Will a Single Triptan Reign Supreme?; 4.3 Lack of Adequate Reimbursement Limits Potential of Anti-Migraine Drugs; 4.4 Choosing the Right Medication; 4.5 Patient Problems with Anti-Migraine drugs; 4.6 What are the Costs of Migraine to the US?

4.6.1 Cost of Migraine

4.6.2 How much Does Migraine Cost the US in Terms of Medical, Missed Workdays and Lost Productivity?; 4.7 FDA Reject Endo�s Attempt to Expand the Label for Frova; 4.8 Complications of the Triptans
Chapter 5 The Prevalence of Migraine: 5.1 What is the Global Prevalence of Migraine?

5.1.1 Why Will the Prevalence of Migraine Increase?; 5.2 Prevalence of Migraine in the US; 5.3 What are the Affects of Migraine on Specific Populations?

5.3.1 Prevalence by Gender

5.3.1.1 Menstrual Migraine

5.3.1.2 Pregnancy and Migraine

5.3.2 Prevalence by Age

5.3.2.1 Migraine in Children

5.3.2.2 Migraine in Later Life
Chapter 6 Pipeline Developments: 6.1 Agents in Phase II of Clinical Development

6.1.1 Addex�s ADX10059

6.1.2 GSK�s 274150, 468816 and 705498; 6.2 Agents in Phase III of Clinical Development

6.2.1 Merck�s MK0974

6.2.2 GSK�s 406381; 6.3 Time is Running out for Pozen & GSK After the FDA Request More Clinical Data on Trexima; 6.4 Pozen�s MT-100; 6.5 Discussion of Current Pipeline Developments; 6.6 Summary of Pipeline Products Phase II and Above
Chapter 7 Alternative Therapies: 7.1 Acupuncture; 7.2 Biofeedback; 7.3 Butterbur Root; 7.4 Chiropractic; 7.5 CoQ10; 7.6 Feverfew Leaf; 7.7 Ginkgo; 7.8 Glucosamine; 7.9 Hormones; 7.9.1 Melatonin; 7.9.2 Estriol; 7.10 Magnesium; 7.11 NTI Tension Suppression System; 7.12 Vitamin B2
Chapter 8 Conclusion: 8.1 Migraine is a Serious Condition with High Prevalence; 8.2 Migraine Market Analysis

8.2.1 The Anti-Migraine Market Will Suffer From the Patent Expiry of its Leading Product

8.2.2 How have Anti-Migraine Drugs Succeeded?

8.2.3 How an Increase in Prevalence will affect Sales Growth

8.2.4 Why is a Growth in the Market Expected?

8.2.5 Niche Markets - Menstrual Migraine

8.2.6 Market Drivers

8.2.7 Market Restraints; 8.3 Geographical Breakdown of Revenues in the Anti-Migraine Market

8.3.1 Sales of Anti-Migraine Drugs Will Decrease in the US from 2007 to 2012

8.3.2 France Will Have the Second-Highest Sales of Anti-Migraine Drugs; 8.4 There are Promising Developments Currently in Mid to Late Stage Clinical Testing; 8.5 Outlook for the Future of the Anti-Migraine Market
Appendix A: About Visiongain
Appendix B: Visiongain Report Evaluation Form
TABLES: Table 2.1 FDA Approved Triptans for Migraine Treatment; Table 2.2 FDA Approved Ergots for Migraine Treatment; Table 2.3 FDA Approved Analgesics for Migraine Treatment; Table 2.4 FDA Approved NSAIDs for Migraine Treatment; Table 3.1 The World Anti-Migraine Market Forecast ($m), 2007-2022; Table 3.2 Imitrex Forecast ($m), 2007-2012; Table 3.3 Zomig Forecast ($m), 2007-2012; Table 3.4 Relpax Forecast ($m), 2007-2012; Table 3.5 Top 10 Leading Companies in the Anti-Migraine Market, Revenue and Market Share, 2006; Table 3.6 Top Ten Countries in the Anti-Migraine Market Revenue ($m) Forecast 2007-2012; Table 4.1 SWOT Analysis of the Anti-Migraine Market; Table 4.2 Economic Burden of Migraine in the US; Table 5.1 Lifetime Prevalence of Headaches among Gender; Table 6.1 Summary of Pipeline Products Phase II and Above, 2007; Table 8.1 Geographical Breakdown of Revenues in the Anti-Migraine Market ($m), 2006-2012
GRAPHS: Graph 1.1 Top Anti-Migraine Products Revenue Forecast ($m), 2007-2012; Graph 3.1 Anti-Migraine World Market Revenue Forecast ($m), 2007-2022; Graph 3.2 Imitrex Revenue Forecast ($m), 2007-2012; Graph 3.3 Zomig Revenue Forecast ($m), 2007-2012; Graph 3.4 Relpax Revenue Forecast ($m), 2007-2012; Graph 3.5 Top 10 Leading Companies in the Anti-Migraine Market ($m), 2006; Graph 8.1 Total Sales of Anti-Migraine Drugs ($m), 2007-2022; Graph 8.2 Sales of the Leading Anti-Migraine Drugs ($m), 2007-2012
CHARTS: Chart 3.1 Leading Companies in the Anti-Migraine Market, Market Share (%), 2006; Chart 3.2 Top Countries in the Anti-Migraine Market, Market Share (%), 2006; Chart 3.3 Top Countries in the Anti-Migraine Market, Market Share (%), 2009; Chart 3.4 Top Countries in the Anti-Migraine Market, Market Share (%), 2012

More Details

Companies Mentioned in this Report
Abbott Laboratories
Addex
Alexza
Almirall Prodesfarma
Apothecon
AstraZeneca
Bayer
Bedford
Bristol-Myers Squibb
CeNeS
Dr. Reddy�s
Elan
Faust Pharmaceuticals
FDA
GD Searle
Geneva Pharmaceuticals
GSK
Harvest Pharms
Houston University
J&J
Lilly
Menarini
Merck & Co
MHRA
Novartis
Odyssey Pharms
Ortho-McNeil
Pfizer
Pharmacia
Pozen
Reckitt Benckiser
Roche
Roxro
Sanofi
UCB
Vernalis
Winston Laboratories
Wyeth